From Wikipedia, the free encyclopedia
Chemical compound
Prusogliptin
![](https://upload.wikimedia.org/wikipedia/commons/thumb/5/57/Prusogliptin.svg/220px-Prusogliptin.svg.png) |
|
Other names | DBPR108 |
---|
|
Legal status |
|
---|
|
(2S,4S)-4-Fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C16H25FN4O2 |
---|
Molar mass | 324.400 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@H](C[C@H]2C#N)F
|
InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1 Key:VQKSCYBKUIDZEI-STQMWFEESA-N
|
Prusogliptin (DBPR108) is an experimental
DPP-4 inhibitor developed by
CSPC Pharmaceutical Group to treat type 2 diabetes.
[1]
[2]
[3]
References
-
^ Xu, Jianping; Ling, Hongwei; Geng, Jianlin; Huang, Yanli; Xie, Ying; Zheng, Huiping; Niu, Huikun; Zhang, Tianhao; Yuan, Jing; Xiao, Xinhua (November 2022).
"Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial". Diabetes, Obesity and Metabolism. 24 (11): 2232–2240.
doi:
10.1111/dom.14810.
PMC
9796963.
PMID
35791646.
-
^ Yeh, Kai-Chia; Yeh, Teng-Kuang; Huang, Chung-Yu; Hu, Chih-Bo; Wang, Min-Hsien; Huang, Yu-Wen; Chou, Ling-Hui; Ho, Hsuan-Hui; Song, Jen-Shin; Hsu, Tsu; Jiaang, Weir-Torn; Chao, Yu-Sheng; Chen, Chiung-Tong (August 2021). "DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity". Life Sciences. 278: 119574.
doi:
10.1016/j.lfs.2021.119574.
PMID
33961850.
S2CID
233999305.
-
^ Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue; Li, Hongmei; Wen, Zhongyuan; Wang, Xinling; Li, Shuangqing; Xiao, Xinhua; Liu, Weijuan; Li, Ziling; Zhang, Lihui; Shao, Shiying; Ye, Shandong; Qin, Guijun; Li, Yiming; Li, Feng; Zhang, Xiaomei; Li, Xuefeng; Peng, Yongde; Deng, Hongyan; Xu, Xiangjin; Zhou, Ligang; Huang, Yanli; Cao, Mengya; Xia, Xuefang; Shi, Mingbiao; Dou, Jing; Yuan, Jing (2 July 2020). "Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial". Current Medical Research and Opinion. 36 (7): 1107–1115.
doi:
10.1080/03007995.2020.1761311.
PMID
32338063.
S2CID
216555956.